EGF and cancer: The in vivo efficacy of mono‐EGF‐IT and bi‐EGF‐IT against HNSCC was assessed using three cancer mouse models: subcutaneous xenografts, orthotopic xenografts in the mouse tongue, and experimental metastasis.